Home > Journals > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Past Issues > The Quarterly Journal of Nuclear Medicine 2001 June;45(2) > The Quarterly Journal of Nuclear Medicine 2001 June;45(2):183-8

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

THE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

A Journal on Nuclear Medicine and Molecular Imaging


A Journal on Nuclear Medicine and Molecular Imaging
Affiliated to the Society of Radiopharmaceutical Sciences and to the International Research Group of Immunoscintigraphy
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index (SciSearch), Scopus
Impact Factor 2,413


eTOC

 

  RADIOPHARMACOLOGY


The Quarterly Journal of Nuclear Medicine 2001 June;45(2):183-8

Copyright © 2009 EDIZIONI MINERVA MEDICA

language: English

PET imaging of hypoxia

Lewis J. S., Welch M. J.

From the Mal­linck­rodt Insti­tute of ­Radiology Wash­ington Uni­ver­sity ­School of Med­i­cine St. ­Louis, MO, USA


FULL TEXT  


Hypoxia in ­tumors has ­been ­related to ­poor ­response to con­ven­tional ther­a­pies. ­This ­paper ­will dis­cuss the ­methods, ­both inva­sive and non-inva­sive, ­used to deter­mine ­hypoxia ­levels ­within ­tumors. PET ­imaging ­with two ­lead com­pounds 18F-flu­o­ro­mis­o­nid­a­zole (18­FMISO) and Cu(II)-dia­cetyl-bis(N4-meth­yl­thi­o­sem­i­car­ba­zone (Cu-­ATSM) and ­their rel­a­tive effec­tive­ness in delin­eating ­hypoxic ­regions ­will be dis­cussed. The advan­tages of Cu-­ATSM-PET ­over ­existing ­imaging ­agents ­will be dis­cussed ­along ­with its poten­tial appli­ca­tion as a ­direct- and/or sur­ro­gate ­marker for the deter­mi­na­tion of onco­log­ical ­hypoxia in ­vivo.

top of page

Publication History

Cite this article as

Corresponding author e-mail